Glenmark and Torrent sign a license agreement to jointly market a drug for diabetes in India
MUMBAI: Glenmark & Torrent Pharma announced that it has signed a non-exclusive sub-license agreement to co-market diabetes drug, sodium glucose co-transporter-2 (SGLT2) inhibitor Remobififlozin Etabonate (Remogliflozin) in India. Under the terms of the agreement, Glenmark will receive an upfront payment, license fees & royalties from Torrent . Glenmark will manufacture & supply Remogliflozin, while Torrent will market the drug under its own trademark ‘Zucator’, says a company statement.
This agreement is an effort to widen access to the latest drug, Remobififlozin Etabonate , indicated for treatment of Type 2 diabetes in India.
In April 2019, Glenmark received approval from the Drugs Controller General of India for Remobififlozin Etabonate after successfully completing Phase-3 clinical trials, & subsequently, launched it under the brand names ‘Remo’ & ‘Remozen’.
Remogliflozin is available at a lower price than other SGLT-2 inhibitors available in the country, he adds.